Osteocytic SOCS3 controls STAT3:STAT1 balance and bone formation [ 2014 - 2016 ]

Research Grant

Researchers: A/Pr Natalie Sims (Principal investigator) ,  E/Pr Thomas Martin

Brief description The most promising new osteoporosis therapy is antibody-based inhibition of the sclerostin protein. We discovered that sclerostin is inhibited by oncostatin M (OSM) only when it binds to a receptor called LIFR, which then activates proteins STAT3 and SOCS3. If OSM binds a different receptor (OSMR) it increases STAT1 activity and destroys bone. This project will determine how to manipulate STAT3, SOCS3, and STAT1 to increase bone formation and provide new treatments for osteoporosis.

Funding Amount $AUD 648,164.51

Funding Scheme Project Grants

Notes Standard Project Grant